Editas Medicine (8EM) Financial Statements
Editas Medicine Financial Overview
Editas Medicine's market cap is currently $338.22M. The company's EPS TTM is $-0.75; its P/E ratio is -3.57; Editas Medicine is estimated to report earnings on November 9, 2026, and the estimated EPS forecast is $-0.16. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 40.52M | $ 32.31M | $ 78.12M | $ 19.71M | $ 25.54M |
| Gross Profit | $ 40.52M | $ -166.93M | $ 72.06M | $ 13.38M | $ 20.49M |
| Operating Income | $ -99.34M | $ -251.15M | $ -169.18M | $ -225.95M | $ -193.15M |
| EBITDA | $ -148.61M | $ -233.11M | $ -147.16M | $ -214.09M | $ -187.45M |
| Net Income | $ -160.06M | $ -237.09M | $ -153.22M | $ -220.43M | $ -192.50M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 146.65M | $ 269.91M | $ 323.11M | $ 344.27M | $ 499.85M |
| Total Assets | $ 186.53M | $ 341.59M | $ 499.15M | $ 514.32M | $ 677.48M |
| Total Debt | $ 76.71M | $ 35.03M | $ 48.54M | $ 43.95M | $ 26.38M |
| Net Debt | $ -69.94M | $ -96.51M | $ -75.11M | $ -97.58M | $ -177.14M |
| Total Liabilities | $ 159.25M | $ 207.31M | $ 150.06M | $ 153.64M | $ 123.84M |
| Stockholders' Equity | $ 27.29M | $ 134.27M | $ 349.10M | $ 360.68M | $ 553.64M |
| Cash Flow | |||||
| Free Cash Flow | $ -165.85M | $ -219.11M | $ -136.90M | $ -181.47M | $ -171.78M |
| Operating Cash Flow | $ -165.24M | $ -210.28M | $ -132.18M | $ -177.35M | $ -163.80M |
| Investing Cash Flow | $ 138.67M | $ 162.15M | $ -3.73M | $ 114.07M | $ -54.47M |
| Financing Cash Flow | $ 40.47M | $ 56.03M | $ 118.04M | $ 1.28M | $ 282.11M |
Currency in USD
